nx_supp_jurisdiction.nx

nx_supp_jurisdiction.nx -- SUPPLEMENT GTM SUITE / MARKET ACCESS rung. Answers "where can this actually be manufactured and sold", per market, with the premarket burden and the review clock made explicit. THE RESULT IS COUNTERINTUITIVE AND IT IS THE POINT OF THIS FILE. The instinct when a market feels closed is to look offshore. For a BOTANICAL or AMINO ACID supplement that instinct is backwards: the United States is the most PERMISSIVE major market in the world, because DSHEA grandfathered pre-1994 ingredients and requires NO premarket approval for them. Every other market here demands premarket authorisation of some kind: US no approval for an old dietary ingredient; 75-day notification only for a NEW one (least burden) Australia listing against a permitted-ingredient list, fast EAEU State Registration certificate (SGR) required BEFORE sale Japan Foods with Function Claims, notify 60 days ahead Canada product licence + NPN before sale EU Novel Food authorisation for anything without significant pre-1997 EU consumption history (most burden) So "go somewhere friendlier" is a real strategy for many industries and a losing one here. The honest reason a botanical stack is easy to sell in the US is that the US barely gates it. THE ONE THING NO JURISDICTION OFFERS. A substance regulated as a MEDICINE has no supplement pathway anywhere on this list -- not the US, not the EAEU, not anywhere. Kisspeptin-10, BPC-157, oxytocin and bremelanotide are medicines or unapproved new drugs in every one of these markets, so sj_any_peptide_supplement_path() returns 0 by construction rather than by promise. A government partnership does not convert a drug into a supplement; it just moves which regulator objects. TIMELINES AND FEES ARE INDICATIVE PLANNING FIGURES, not quotes -- they move with dossier quality, ingredient novelty, and local counsel. sj_estimate_is_indicative() exists so nothing downstream presents them as commitments. Sanctions, banking access and export controls are a SEPARATE analysis this file does not attempt and must not be read as clearing. Grounding (cited; researcher-groundable): dshea_1994_old_dietary_ingredient_no_premarket_approval